Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of ...

A nurse whose father died after being given infected blood has said he would have been “disgusted” at the way bereaved ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

Liver disease patients are falling through the cracks and not getting the treatment they need. Support from people with lived experience of disease could bridge the gap.

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

NPR looked at the Foundation for Government Accountability, a conservative policy think tank that's behind legislation to ...

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...

Primary hepatitis C virus (HCV) care cascade outcomes are low among children with HCV, with racial and ethnic disparities ...

A drug and alcohol service in Leeds has said it has "micro-eliminated" hepatitis C - meaning it has identified, treated and cured individuals most at risk of the virus. Forward Leeds has worked ...